The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 95b88dcb5c38171a-LAX IP: 47.97.18.252 UTC time: 2025-07-07T16:00:17+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4